Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients ...

Pfizer Settles Its Subsidiary’s Kickback Allegations for Nearly $60 Million - Pfizer Inc. agreed to pay over $59,746,277 to ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...

Zai Lab (ZLAB) and Pfizer (PFE) announced a strategic collaboration for the novel antibacterial drug Xacduro in mainland China. Pfizer’s affiliated companies will be exclusively authorized to ...

World Health Organization (WHO) partners Unitaid have announced an agreement with the Pfizer laboratories to manufacture generic oral drugs to be used against COVID-19. Unitaid spokesman Hervé ...

Pfizer PFE-2.06%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN-0.11%decrease; red down pointing triangle for 2.50 billion ...

Jan 15 (Reuters) - Pfizer (PFE.N), opens new tab will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon (HLN.L), opens new tab, lowering its stake in the British consumer healthcare ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

(Bloomberg) -- Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste. The deal raised around £2.5 billion ($3.1 billion ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of $33.00. Discover outperforming stocks and invest ...